JPMorgan analyst James Gordon raised the firm’s price target on AstraZeneca to 13,500 GBp from 12,500 GBp and keeps an Overweight rating on the shares.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AZN:
- AstraZeneca announces Calquence approved in Japan to treat CLL
- AstraZeneca announces Imfinzi, Imjudo approved in Japan to treat three cancers
- AstraZeneca’s Lynparza approved in E.U. as first line treatment in mCRPC
- Merck, AstraZeneca: LYNPARZA/abiraterone and prednisone combo approved in EU
- AstraZeneca’s Imfinzi+chemotherapy approved in E.U. in BTC patients
